Collagenous colitis presenting with skip lesions mimicking Crohn's disease and complicated by intestinal obstruction

Hui, Christy Y.; Hui, Nyee Kit

doi:10.1111/1751-2980.12507

Cited by 1 publication

(1 citation statement)

References 13 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Crohn’s disease (CD) is a chronic relapsing inflammation of the gut, which causes significant impairment of quality of life with a rising incidence and prevalence during recent decades[ 1 , 2 ]. Although the clinical manifestations and pathologic progress of CD are different, fibrosis of intestinal organization and strictures induced by transmural inflammation will eventually cause intestinal obstruction, which is the characteristic clinical manifestation[ 3 - 5 ]. In addition, more than 1/3 of CD patients need at least one intestinal operation in their lives, while 70% of the CD patients with fibrosis strictures need partial resection of the intestinal tract within 10 years of disease progression, and 70%-90% patients will have a recurrence of anastomotic strictures and over 50% patients will form new strictures[ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Total flavone of Abelmoschus manihot suppresses epithelial-mesenchymal transition via interfering transforming growth factor-β1 signaling in Crohn’s disease intestinal fibrosis

Yang¹,

Zhu²,

Li³

et al. 2018

WJG

View full text Add to dashboard Cite

AIMTo explore the role and mechanism of total flavone of Abelmoschus manihot (TFA) on epithelial-mesenchymal transition (EMT) progress of Crohn’s disease (CD) intestinal fibrosis.METHODSFirst, CCK-8 assay was performed to assess TFA on the viability of intestinal epithelial (IEC-6) cells and select the optimal concentrations of TFA for our further studies. Then cell morphology, wound healing and transwell assays were performed to examine the effect of TFA on morphology, migration and invasion of IEC-6 cells treated with TGF-β1. In addition, immunofluorescence, real-time PCR analysis (qRT-PCR) and western blotting assays were carried out to detect the impact of TFA on EMT progress. Moreover, western blotting assay was performed to evaluate the function of TFA on the Smad and MAPK signaling pathways. Further, the role of co-treatment of TFA and si-Smad or MAPK inhibitors has been examined by qRT-PCR, western blotting, morphology, wound healing and transwell assays.RESULTSIn this study, TFA promoted transforming growth factor-β1 (TGF-β1)-induced (IEC-6) morphological change, migration and invasion, and increased the expression of epithelial markers and reduced the levels of mesenchymal markers, along with the inactivation of Smad and MAPK signaling pathways. Moreover, we revealed that si-Smad and MAPK inhibitors effectively attenuated TGF-β1-induced EMT in IEC-6 cells. Importantly, co-treatment of TFA and si-Smad or MAPK inhibitors had better inhibitory effects on TGF-β1-induced EMT in IEC-6 cells than either one of them.CONCLUSIONThese findings could provide new insight into the molecular mechanisms of TFA on TGF-β1-induced EMT in IEC-6 cells and TFA is expected to advance as a new therapy to treat CD intestinal fibrosis.

show abstract